153 related articles for article (PubMed ID: 34719640)
1. Variation in Expression of Cytochrome P450 3A Isoforms and Toxicological Effects: Endo- and Exogenous Substances as Regulatory Factors and Substrates.
Fujino C; Sanoh S; Katsura T
Biol Pharm Bull; 2021; 44(11):1617-1634. PubMed ID: 34719640
[TBL] [Abstract][Full Text] [Related]
2. Genetic contribution to variable human CYP3A-mediated metabolism.
Lamba JK; Lin YS; Schuetz EG; Thummel KE
Adv Drug Deliv Rev; 2002 Nov; 54(10):1271-94. PubMed ID: 12406645
[TBL] [Abstract][Full Text] [Related]
3. Comparison of steroid hormone hydroxylation mediated by cytochrome P450 3A subfamilies.
Niwa T; Okamoto A; Narita K; Toyota M; Kato K; Kobayashi K; Sasaki S
Arch Biochem Biophys; 2020 Mar; 682():108283. PubMed ID: 32001245
[TBL] [Abstract][Full Text] [Related]
4. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.
Williams JA; Ring BJ; Cantrell VE; Jones DR; Eckstein J; Ruterbories K; Hamman MA; Hall SD; Wrighton SA
Drug Metab Dispos; 2002 Aug; 30(8):883-91. PubMed ID: 12124305
[TBL] [Abstract][Full Text] [Related]
5. Cytochrome P450 3A: ontogeny and drug disposition.
de Wildt SN; Kearns GL; Leeder JS; van den Anker JN
Clin Pharmacokinet; 1999 Dec; 37(6):485-505. PubMed ID: 10628899
[TBL] [Abstract][Full Text] [Related]
6. Cytochrome P450 3A expression in the human fetal liver: evidence that CYP3A5 is expressed in only a limited number of fetal livers.
Hakkola J; Raunio H; Purkunen R; Saarikoski S; Vähäkangas K; Pelkonen O; Edwards RJ; Boobis AR; Pasanen M
Biol Neonate; 2001; 80(3):193-201. PubMed ID: 11585982
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the Stimulatory and Inhibitory Effects of Steroid Hormones and α-Naphthoflavone on Steroid Hormone Hydroxylation Catalyzed by Human Cytochrome P450 3A Subfamilies.
Niwa T; Toyota M; Kawasaki H; Ishii R; Sasaki S
Biol Pharm Bull; 2021; 44(4):579-584. PubMed ID: 33790108
[TBL] [Abstract][Full Text] [Related]
8. Stereoselective Oxidation Kinetics of Deoxycholate in Recombinant and Microsomal CYP3A Enzymes: Deoxycholate 19-Hydroxylation Is an In Vitro Marker of CYP3A7 Activity.
Chen YJ; Zhang J; Zhu PP; Tan XW; Lin QH; Wang WX; Yin SS; Gao LZ; Su MM; Liu CX; Xu L; Jia W; Sevrioukova IF; Lan K
Drug Metab Dispos; 2019 Jun; 47(6):574-581. PubMed ID: 30918015
[TBL] [Abstract][Full Text] [Related]
9. Expression of CYP3A in the human liver--evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth.
Lacroix D; Sonnier M; Moncion A; Cheron G; Cresteil T
Eur J Biochem; 1997 Jul; 247(2):625-34. PubMed ID: 9266706
[TBL] [Abstract][Full Text] [Related]
10. CYP3A isoforms in Ewing's sarcoma tumours: an immunohistochemical study with clinical correlation.
Zia H; Murray GI; Vyhlidal CA; Leeder JS; Anwar AE; Bui MM; Ahmed AA
Int J Exp Pathol; 2015 Apr; 96(2):81-6. PubMed ID: 25670065
[TBL] [Abstract][Full Text] [Related]
11. Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety.
Yamaori S; Ebisawa J; Okushima Y; Yamamoto I; Watanabe K
Life Sci; 2011 Apr; 88(15-16):730-6. PubMed ID: 21356216
[TBL] [Abstract][Full Text] [Related]
12. Metabolism of alfentanil by cytochrome p4503a (cyp3a) enzymes.
Klees TM; Sheffels P; Dale O; Kharasch ED
Drug Metab Dispos; 2005 Mar; 33(3):303-11. PubMed ID: 15557344
[TBL] [Abstract][Full Text] [Related]
13. Contribution of three CYP3A isoforms to metabolism of R- and S-warfarin.
Jones DR; Kim SY; Boysen G; Yun CH; Miller GP
Drug Metab Lett; 2010 Dec; 4(4):213-9. PubMed ID: 20615193
[TBL] [Abstract][Full Text] [Related]
14. Differential catalytic properties in metabolism of endogenous and exogenous substrates among CYP3A enzymes expressed in COS-7 cells.
Ohmori S; Nakasa H; Asanome K; Kurose Y; Ishii I; Hosokawa M; Kitada M
Biochim Biophys Acta; 1998 May; 1380(3):297-304. PubMed ID: 9555064
[TBL] [Abstract][Full Text] [Related]
15. The Role of CYP3A in Health and Disease.
Klyushova LS; Perepechaeva ML; Grishanova AY
Biomedicines; 2022 Oct; 10(11):. PubMed ID: 36359206
[TBL] [Abstract][Full Text] [Related]
16.
Work HM; Kandel SE; Lampe JN
Drug Metab Dispos; 2024 May; ():. PubMed ID: 38702193
[TBL] [Abstract][Full Text] [Related]
17. Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA.
Koch I; Weil R; Wolbold R; Brockmöller J; Hustert E; Burk O; Nuessler A; Neuhaus P; Eichelbaum M; Zanger U; Wojnowski L
Drug Metab Dispos; 2002 Oct; 30(10):1108-14. PubMed ID: 12228187
[TBL] [Abstract][Full Text] [Related]
18. Individualized Tacrolimus Therapy for Pediatric Nephrotic Syndrome: Considerations for Ontogeny and Pharmacogenetics of CYP3A.
Sun JY; Xu ZJ; Sun F; Guo HL; Ding XS; Chen F; Xu J
Curr Pharm Des; 2018; 24(24):2765-2773. PubMed ID: 30156148
[TBL] [Abstract][Full Text] [Related]
19. Contribution of CYP3A isoforms to dealkylation of PDE5 inhibitors: a comparison between sildenafil N-demethylation and tadalafil demethylenation.
Takahiro R; Nakamura S; Kohno H; Yoshimura N; Nakamura T; Ozawa S; Hirono K; Ichida F; Taguchi M
Biol Pharm Bull; 2015; 38(1):58-65. PubMed ID: 25744459
[TBL] [Abstract][Full Text] [Related]
20. Effects of cytochrome b(5) on drug oxidation activities of human cytochrome P450 (CYP) 3As: similarity of CYP3A5 with CYP3A4 but not CYP3A7.
Yamaori S; Yamazaki H; Suzuki A; Yamada A; Tani H; Kamidate T; Fujita Ki; Kamataki T
Biochem Pharmacol; 2003 Dec; 66(12):2333-40. PubMed ID: 14637191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
